Jun 26, 2020 / 03:30PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to today's program entitled Bristol Myers Squibb 3-Part Investor Series: Immunology & Cardiovascular. (Operator Instructions) As a reminder, today's program may be recorded.
Now I'd like to introduce your host for today's program, Tim Power, Vice President of Investor Relations. Please go ahead, sir.
Timothy Power - Bristol-Myers Squibb Company - VP & Head of IR
Thanks, Jonathan, and good morning, everyone. Thanks for joining us again today. This morning, we'll have the concluding session from our 3-part Investor Series, focused on immunology and cardiovascular. And once again, we'll have a presentation followed by a Q&A session. So if you're not participating in the webcast, you can go ahead and download the materials at bms.com.
Joining me this morning for the presentation are Giovanni Caforio, Chairman and Chief Executive Officer; Samit Hirawat, Chief Medical Officer, Global Drug Development; Chris Boerner, Chief Commercialization Officer; and David Elkins, Chief
Bristol-Myers Squibb Co Three-Part Investor Series: Immunology and Cardiovascular Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot